Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs Bristol-Myers Squibb Co (BMY) Price & Performance

Bandwidth IncTrade
Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs Bristol-Myers Squibb Co — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 78.3× Bandwidth Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.

BANDBMY
Market Cap
$1.66B$129.94B
Sector
TechnologyHealth
52-Week High
$78.44$65.89
52-Week Low
$12.82$42.60
Enterprise Value
$2.04B$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth (BAND) trades at $51.97, down 1.4% over 24 hours, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $0.37 versus $0.3652 expected, and raised its full-year outlook on AI-driven demand growth. Revenue climbed 22% year-over-year to $220 million, though net income margins remain thin at 0.27% for 2026.

The stock offers upside to the $75.25 analyst consensus target, fueled by AI adoption and enterprise wins, but risks include high valuation multiples like a 34.08 EV/EBITDA and competitive pressures in cloud communications. Execution on profitability improvements will be critical for sustaining gains.

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY